Brought to you by 
Xenon gets $58mm from Warner-Lambert in HDL cholesterol deal
08 Dec 2015
Executive Summary
In a three-year deal, private Canadian genomics company Xenon Genetics has licensed its drug discovery technology to Warner-Lambert, which will get exclusive worldwide rights to any compounds identified to treat low HDL cholesterol levels. For the first product commercialized, W-L will pay Xenon $57.75mm ($Cdn87mm) in up-fronts, research funding, equity and milestones, and additionally will pay royalties on product sales.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com